MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include:(CAD) Q3 2025 % Change vs.Q3 2024 YTD 2025 % Change vs.YTD 2024 Trailing Twelve Months (TTM) Sept 30, 2025 % Change vs.TTM Sept 30, 2024Canadian Pharma Sales 9,864,254 +19% 28,351,130 +16% 36,897,581 +14%International Pharma Sales 1,153,742 +94% 3,134,572 +316% 3,311,306 +310%Legacy Business Sales 1,203,808 +83% 1,894,358 +73% 1,967,857 +48%Total Company Sales 12,221,804 +28% 33,380,060 +27% 42,176,744 +22%EBITDA¹ 3,632,399 +27% 9,594,195 +35% 11,835,307 +35%Net Income After Taxes (NIAT) 2,682,340 +16% 7,020,444 +24% 8,633,638 +21%Fully Diluted EPS 0.23 +19% 0.61 +28% 0.75 +25%             Return...

– Q4 Sales increase 29% to $353 Million – Q4 Entered Orders increase 30% to $321 Million – Q4 GAAP EPS from Continuing Operations increases 14% to $1.73 – Q4 Adjusted EPS from Continuing Operations increases 30% to $2.32 – FY 2025 Sales increase 19% to $1.1 Billion – FY 2025 Entered Orders increase 57% to $1.6 Billion – FY 2025 GAAP EPS from Continuing Operations increases 13% to $4.49 – FY 2025 Adjusted EPS from Continuing Operations increases 26% to $6.03 – St. Louis, Nov. 20, 2025 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the fourth quarter and fiscal year ended September 30, 2025 (Q4 2025 and FY 2025, respectively). During Q4 2025, the Company completed the sale of VACCO Industries. The VACCO operating...

TRAVERSE CITY, Mich., Nov. 20, 2025 (GLOBE NEWSWIRE) — MachTen, Inc. (OTC: MACT) today announced financial results for the third quarter ended September 30, 2025. “Michigan Broadband delivered another quarter of disciplined execution, expanding our fiber footprint while continuing to invest in our teams, systems and capabilities that support scalable growth,” said Dan Miller, Chief Executive Officer. “We remain committed to building the most reliable network in every community we serve, driving long-term value for our customers, partners, and shareholders.” Third Quarter 2025 Financial HighlightsRevenue: $4.3 million was approximately flat compared to the third quarter of 2024, as new fiber-optic subscribers were offset by declines in copper-based voice and DSL customers. We expect revenue to improve in 2026 from an increase...

ST. LOUIS, Nov. 20, 2025 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported selected operating results for October 31, 2025, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said, “Total client assets and fee-based client assets reached record highs, increasing 12% and 18% year-over-year, respectively, driven by market appreciation and strong net asset inflows. Treasury deposits grew 35% over the prior year, reflecting the effectiveness of our venture and fund banking deposit initiatives, essentially offsetting declines in client money market and insured product balances. Bank loans rose 1% since September, supported by higher...

Maroussi, Greece, November 20, 2025 – Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company”, “we”, “our”, “us” or “Pyxis Tankers”), an international diversified shipping company, today announced unaudited results for the three and nine month periods ended September 30, 2025. For the three months ended September 30, 2025, our revenues, net, were $9.7 million. For the same period, our time charter equivalent (“TCE”) revenues were $8.9 million, a decrease of $2.7 million, or 23.5%, over the comparable period in 2024. Our net income attributable to common shareholders for the third quarter ended September 30, 2025 was $1.2 million, compared to net income of $3.6 million for the same period in 2024. For the third quarter of 2025, the net income per common share was $0.11 basic and diluted compared to a net income per common share of $0.34...

– Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study – – Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement towards commercial readiness – – Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART trial – – Cash, cash equivalents & deposits balance of $75.9 million provides runway for continued clinical advancement and commercial preparation – JERUSALEM, Nov. 20, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported third quarter 2025 financial results...

Helstu atriði úr fjárhagsuppgjöri 3F 2025Vörusala var 111 m€ á fjórðungnum samanborið við 110 m€ á þriðja fjórðungi 2024 Hagnaður var 29 m€ á fjórðungnum samanborið við 19 m€ á þriðja fjórðungi 2024 EBITDA var 42 m€ og EBITDA hlutfall 37,3% Eignir hafa lækkað um 13 m€ frá áramótum og voru 983 m€ í lok tímabilsins Eigið fé þann 30. september 2025 var 505 m€ og eignfjárhlutfall 51,4%Guðmundur Kristjánsson, forstjóri: „Afkoma þriðja fjórðungs er góð og eru það tveir þættir sem skipta mestu máli. Veiðar og vinnsla á makríl gengu vel og verð á sjávarafurðum er hátt um þessar mundir. Þegar við horfum til seinustu 12 mánaða er ávöxtun eigin fjár 12%. Í september var tilkynnt um kauptilboð félagsins í allt hlutafé Lýsis hf. Með kaupunum sér Brim mikil samlegðar- og sóknarfæri bæði tengt hráefnaöflun Lýsis og fyrir Brim til að ná lengra í...

AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) — Golden Triangle Ventures, Inc. released its Quarterly Report for the period ending September 30, 2025, reflecting a pivotal quarter defined by meaningful revenue growth, improved profitability, strengthened shareholder equity, and the early results of the Company’s comprehensive restructuring under new leadership. Q3 2025 marks a clear turning point in the Company’s trajectory — a shift from legacy challenges to a clean, growth-ready platform supported by strong operational performance. Q3 2025 Financial Performance According to the Company’s official Q3 Quarterly Report, Golden Triangle Ventures generated:Total Revenue: $2,051,088 Construction Revenue: $1,511,140 Gross Profit: $1,711,097 Net Income: $1,007,767, compared to a $(388,921) loss in Q3 2024 Year-to-date Net Income: $1,020,055,...

Company Successfully Advances Several New Branding and Marketing Initiatives Strengthens Balance Sheet; Converts $27 Million of Corporate Liabilities into Equity New HealthMD Subsidiary to Deliver New Holistic Products, Integrate AI TechLOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) — Limitless X Holdings Inc. (OTCQX: LIMX), a global health, wellness, and lifestyle company founded by entrepreneur Jas Mathur, today announced operational and financial highlights of its third quarter of 2025 ended September 30, 2025. Results reflect several new marketing initiatives, including a pivot to bring most sales and marketing activities in-house, which is expected to increase ROI and raise profit margins, as well as a restructuring to strengthen the Company’s financial position. Q3 2025 and Recent Operating HighlightsFormed HealthMD Inc.,...

In the nine months of 2025, the net turnover was 1 444.4 thousand. EUR, which is 21.0% more than in the nine months of the previous year, but the profit before taxes was 95.5 thousand. EUR – by 11.1 thousand EUR more compared to the corresponding period of the previous year. JSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ (hereinafter referred to as the Company) is the only producer of high-quality breeding bull semen and one of the largest suppliers of it in Latvia. The second largest field of the Company’s basic economic activities is the milk testing services. The Company also provides other breeding related services – consultations on issues of cattle breeding, feeding and keeping, evaluation of cow exterior, artificial insemination of cows, initial processing of the supervisory data. The company offers Latvian farms the...